Medigene – executive interview

Medigene (FSE: MDG1) is a publicly listed, Germany-based, immuno-oncology platform company focused on the development of T cell receptor (TCR)-guided therapies with the aim of effectively eliminating cancer. Medigene has a broad and active pipeline focused on a range of modalities. Notably, lead programme MDG1015 is a first-in-class, third-generation T cell receptor-engineered T cell (TCR-T) therapy, for which, the company recently received US FDA clearance for its investigational new drug application for multiple solid tumour indications. MDG1015 is expected to enter the clinic by end-2024, subject to additional financing.

In this video we speak to Dr Kirsty Crame, MD, Head of Clinical Strategy and Development at Medigene, where we cover how Medigene is differentiated within the field of precision immunotherapy, the company’s modular End-to-End Platform approach and its ongoing partnerships with BioNTech, Regeneron and, most recently, WuXi Biologics. Dr Kirsty Crame, MD, also discusses the key milestones and catalysts for investors to watch out for across the next 12–18 months.